Laboratory Developed Tests –
Irreplaceable Tools for Innovative Patient Care

Clinical laboratory tests provide the information necessary for physicians and other health care providers to make treatment decisions for their patients. Laboratories that perform complex clinical testing must meet stringent regulatory requirements under the federal Clinical Laboratory Improvement Amendments (CLIA). In addition, a number of states also regulate clinical laboratories. Laboratories also adhere to established professional society and laboratory practice guidelines and obtain certifications and/or accreditations as appropriate for their particular discipline. These regulations, guidelines, and certifications ensure that patients receive reliable and accurate laboratory testing services.

What is an in vitro diagnostic test?
In vitro diagnostic (IVD) tests are used to analyze specimens from the human body, including blood, urine, tissue, nasopharyngeal samples, or saliva. These tests are manufactured and sold to laboratories by third-party vendors. Manufacturers produce and market IVD tests, which are typically performed on manufacturer-specific platforms (instruments), to diagnose, prevent, or manage the treatment of specific diseases. IVDs can be used in a number of settings, including clinical laboratories, physician offices, hospitals, and even at home—for example, an over the counter pregnancy test. IVD tests and test components are considered medical devices and are therefore regulated by the Food and Drug Administration (FDA) under a risk-based framework.

What are Laboratory Developed Tests (LDTs)?
Laboratory Developed Tests (LDTs) are testing processes that are created, validated, and performed in a single CLIA-certified laboratory and are not marketed for sale or use in other laboratories. LDTs play a significant role in patient care. The vast majority of LDTs simply detect and/or quantify the presence of something in the human body, such as a virus, antibody, or toxic chemical, to aid in the detection of a disease or health condition or to monitor a drug treatment or therapy. Some LDTs—like those used for early cancer detection or cancer risk factors—look for genetic variations and require automated instrumentation or software-based algorithms to determine an individual's risk for a disease or disorder.

Why do patients need LDTs?
Manufactured and commercialized IVDs do not nearly cover the full spectrum of human diseases. LDTs are needed to fill these gaps and provide critical knowledge to health care practitioners. Because LDTs are developed and used by professional laboratory personnel who provide expert analyses, LDTs are inherently different from FDA-regulated IVD tests.

The Value of LDTs: Pandemic Response
LDTs made the nation’s COVID-19 response possible. Early mistakes in the development of an IVD for SARS-CoV-2 led to weeks long delays in access to authorized COVID-19 test kits. In response, laboratories stepped up and developed LDTs, allowing physicians and their public health partners to identify COVID-19 positive patients and respond to the novel SARS-CoV-2 virus – and demonstrating the value of LDTs in a public health emergency.

National Independent Laboratory Association
906 Olive Street, Suite 1200, St. Louis, Missouri 63101
Email: nila@nila-usa.org | Web: www.nila-usa.org | Tel: (314)241-1445
The expertise of experienced laboratory professionals are required to design, develop, validate, perform, and improve LDTs. Laboratory professionals design LDTs and set their analytic parameters. Laboratory professionals also consult with the treating practitioner, who uses his or her medical judgment to care for the patient. As technology evolves and new infectious agents emerge, laboratory professionals are able to rapidly validate and implement novel LDTs—often well before commercial, FDA-approved IVDs are available—that aid in medical care and help respond to public health emergencies, like COVID-19 and the Zika virus.

In addition, LDTs are frequently more accurate, reliable, and relevant to patient care than FDA-approved IVDs. Because IVD tests must undergo FDA approval, test manufacturers have a disincentive to improve or refine IVD tests because modifications to an existing IVD test may require additional regulatory review. Because LDTs do not require FDA approval, laboratories are able to safely and accurately modify existing LDTs to improve their performance, meet the needs of patients, and respond to emerging threats.

The vast majority of LDTs identify and/or quantify the presence or absence of a substance, infectious agent, chemical, or other property. More than 83% of LDTs offered by NILA-member laboratories simply identify or quantify the presence of a substance. Only a few LDTs use sophisticated proprietary software, algorithms or probabilistic assessments to direct clinical care. As a result, most LDTs pose low risks to patients and fall within the traditional regulatory authority (CLIA, state regulations) that already apply to laboratories.

How are laboratories, IVDs and LDTs regulated?
The Centers for Medicare and Medicaid Services (CMS) regulates most clinical laboratory testing through the Clinical Laboratory Improvement Amendments (CLIA). CLIA holds laboratories and their staff to specific standards, while allowing laboratory professionals to use their professional judgment in performing tests. Under CLIA, CMS regulates clinical laboratories and the testing processes that they execute, including LDTs. While FDA oversight of IVDs focuses only on a manufacturer’s test kit or instrument, CLIA regulates the quality and performance of IVDs and LDTs in the field. Specifically, CLIA assesses the ability of a test to accurately detect and measure the substance of interest. Prior to releasing the result of any LDT, a laboratory must establish the LDT’s analytical validity (the tests ability to measure accurately and reliably a substance or organism of interest) within that specific laboratory environment. The analytical validity of LDTs is also reviewed by CMS, or an agency acting on CMS’
How does proficiency testing help laboratories ensure the validity and accuracy of LDTs?

Laboratories use a CLIA-mandated process, called proficiency testing, to ensure the validity and accuracy of clinical diagnostic laboratory tests, including LDTs. Proficiency testing is an external quality control measure to evaluate the performance of tests in a laboratory. Required under CLIA, laboratories must enroll in an HHS-approved proficiency testing program. On a scheduled basis, a set of unknown samples are forwarded to a laboratory to analyze through their regular testing process. Results are reported back to the proficiency testing program and graded to monitor the laboratory’s performance and the accuracy of the test when performed “in the field.” In the absence of externally available proficiency tests, CLIA requires a laboratory performing an LDT to develop another means of “challenging” the test to demonstrate its validity and accuracy.

Most laboratories that offer LDTs use CLIA-approved proficiency testing programs to ensure that the tests they offer are accurate and reliable. This CLIA-mandated process ensures that all tests performed in a laboratory—both IVDs and LDTs—are analytically valid and capable of performing accurately and reliably. Physicians and other qualified healthcare providers then use their clinical expertise to determine which tests are needed to diagnose a disease or monitor a patient’s health and then they evaluate the test results in light of the patient’s symptoms. Proficiency testing gives confidence to medical providers that, when they order tests for their patients, they will receive reliable and accurate results.

What would FDA regulation of LDTs mean for patients and laboratories?

Historically, the FDA has not regulated LDTs, deferring to CLIA to oversee the development and performance of LDTs. The advent of more sophisticated LDTs, however, has raised questions about whether existing CLIA regulations are adequate to regulate LDTs that use proprietary algorithms or machine learning technology. Current proposals to extend FDA authority to regulate all LDTs, while intended to provide additional assurances to patients, are likely to cause unintended consequences that will limit access to care and impose ill-conceived regulatory burdens.

**Restricted Access to Innovative Technologies.**

FDA regulation of LDTs may unintentionally restrict patient access to breakthroughs in laboratory technology and discourage laboratory innovation that improves patient health and safety. Duplicative regulations on LDTs are likely to make the development of LDTs prohibitively expensive for all but the largest clinical laboratories, restricting patient access to innovative technology and advances in the diagnosis and treatment of cancer and other diseases. In addition, FDA oversight of LDTs is also likely to create perverse incentives for laboratories to avoid bringing new products to market, or delay needed upgrades to existing tests, for fear of

---

**The Value of LDTs: Better Allergen Testing**

LDTs are frequently more accurate than existing IVDs. Unlike LDTs, IVDs are developed with wide commercialization in mind, meaning that the quality may be lower than tests developed by laboratories. As a result, laboratories frequently create their own LDTs to achieve more precise or specific results. For example, laboratories have developed LDTs to detect more than 400 different allergens, most of which are not available from IVD manufacturers. These unique tests help physicians devise better treatments for patients. Laboratories have improved the quality of allergen results with LDT technologies that manufacturers have been reluctant to adopt due in part to the regulatory burden of FDA review.
need to wade through additional FDA regulatory requirements that prevent improvements to
tests from reaching patients more quickly, thus inadvertently leading to less accurate test
results.

**Duplicative Requirements & Regulatory Delay.**
Current proposals to impose FDA regulation on the development and use of LDTs fail to
recognize the existing protections that CLIA and state law provide against patient harm.
Laboratory innovation moves faster than government regulators—meaning FDA regulation of
LDTs will inevitably lead to delayed access to innovative diagnostic technologies. Even outside
the strain of a pandemic, FDA review is frequently criticized as burdensome, slow, and costly.
Adding numerous LDTs to FDA’s portfolio—even just test registration—will be costly to the FDA,
the laboratory industry, and patients. FDA resources are better focused on assessing the safety
and efficacy of treatments and devices, and physicians and other primary health care providers
are best equipped to use their clinical judgment to assess the clinical relevance of the
information they request from laboratories. Policy makers should reserve additional oversight, if
any, for those tests that pose the highest risk of harm to patients and that most clearly fall
outside the purview of existing safety protections provided by CLIA and state laws.

**Unnecessary Regulatory Burden.**
Current proposals to regulate LDTs will also impose significant administrative burdens on
laboratories with no obvious tie to patient safety. Requirements that laboratories register
existing LDTs with the FDA, for example, serve little purpose except to create a catalog of tests
that will be difficult for patients to understand, costly for laboratories to populate, and
challenging for the FDA to maintain. Additionally, the FDA has proposed a fee per test on
laboratories performing LDTs to self-fund this proposed program. Such fees will stifle
innovation, especially for infrequently ordered, but necessary tests, such as those used to help
diagnose or guide treatment of orphan diseases.

There is no compelling reason to extend registration requirements to tests that pose little risk to
patients and that are performed safely and accurately in the field. Registration requirements are
particularly challenging for smaller community and regional clinical laboratories, some of whom
specialize in providing LDTs that other laboratories choose not to provide. In the face of these
regulatory burdens, some laboratories may choose to narrow their test menus, limiting the
testing options available to clinicians and their patients. A more appropriate, tailored approach
would limit registration requirements to only those tests that pose the highest risk to patients or
have a limited record of use in the field.

**How can policymakers avoid stifling innovation and limiting access to needed care?**
To avoid an unnecessary regulatory burden and increased costs for both patients and providers,
policymakers should avoid imposing requirements that duplicate existing state and federal safeguards.
In addition, lawmakers should not create test registration requirements for LDTs that present a low risk
to patient safety or public health—particularly for those tests already relied upon by providers and
patients. Finally, regulatory approaches to LDTs should be clear, transparent, consistent, and not impose
undue costs on laboratories or patients.

Laboratories take seriously their obligation to provide reliable, accurate testing services to clinicians and
patients. By taking a more tailored approach to regulating LDTs, Congress can avoid unnecessary costs
and delays to innovation and patient care.